公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses.
インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→
| 損益計算書 | TTM | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 | 2015-10-31 | 2014-10-31 | 2013-10-31 | 2012-10-31 | 2011-10-31 | 2010-10-31 | 2009-10-31 | 2008-10-31 | 2007-10-31 | 2006-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高合計 | $7.2B | $6.9B | $6.5B | $6.8B | $6.8B | $6.3B | $5.3B | $5.2B | $4.9B | $4.5B | $4.2B | $4.0B | $4.0B | $3.9B | $6.9B | $6.6B | $5.4B | $4.5B | $5.8B | $5.4B | $5.0B |
| 売上総利益 | $3.8B | $3.6B | $3.5B | $3.5B | $3.7B | $3.4B | $2.8B | $2.8B | $2.7B | $2.4B | $2.2B | $2.0B | $2.0B | $1.9B | $3.6B | $3.5B | $2.9B | $2.3B | $3.2B | $3.0B | $2.7B |
| 売上総利益率 % | 53.0% | 52.4% | 54.3% | 50.7% | 54.4% | 53.9% | 53.1% | 54.3% | 54.7% | 53.9% | 52.3% | 50.5% | 48.8% | 49.0% | 52.5% | 53.3% | 53.8% | 51.1% | 55.4% | 54.8% | 53.4% |
| 営業利益（EBIT） | $1.6B | $1.5B | $1.5B | $1.4B | $1.6B | $1.3B | $846M | $941M | $904M | $841M | $615M | $522M | $419M | $386M | $1.1B | $1.1B | $566M | $47M | $795M | $584M | $464M |
| 営業利益率 % | 21.5% | 21.3% | 22.9% | 19.8% | 23.6% | 21.3% | 15.8% | 18.2% | 18.4% | 18.8% | 14.6% | 12.9% | 10.3% | 9.9% | 16.3% | 16.2% | 10.4% | 1.1% | 13.8% | 10.8% | 9.3% |
| 当期純利益 | $1.4B | $1.3B | $1.3B | $1.2B | $1.3B | $1.2B | $719M | $1.1B | $316M | $684M | $460M | $401M | $549M | $724M | $1.2B | $1.0B | $684M | ($31M) | $693M | $638M | $3.3B |
| 純利益率 % | 19.6% | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% | 13.5% | 20.7% | 6.4% | 15.3% | 10.9% | 9.9% | 13.6% | 18.6% | 16.8% | 15.3% | 12.6% | -0.7% | 12.0% | 11.8% | 66.5% |
| EBITDA | $2.0B | $1.8B | $1.9B | $1.7B | $1.9B | $1.8B | $1.2B | $1.2B | $1.2B | $1.1B | $863M | $799M | $723M | $758M | $1.4B | $1.4B | $1.0B | $257M | $1.1B | $775M | $634M |
| 1株当たり利益（EPS） | $5.81 | $5.58 | $5.29 | $5.45 | $5.21 | $4.34 | $3.28 | $3.12 | $2.79 | $2.37 | $1.98 | $1.73 | $3.05 | $2.89 | $3.12 | $2.95 | $2.00 | $0.80 | $1.95 | $1.55 | $1.54 |
| 発行済株式数（百万株） | 284M | 284M | 291M | 296M | 300M | 307M | 312M | 318M | 325M | 326M | 329M | 335M | 338M | 345M | 353M | 355M | 353M | 346M | 371M | 406M | 441M |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は A のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/A
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms